Immediate Impact
1 from Science/Nature 50 standout
Citing Papers
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2024 Standout
RNAi-based drug design: considerations and future directions
2024 Standout
Works of Ann Eldred being referenced
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
2021
ABT‐719 for the Prevention of Acute Kidney Injury in Patients Undergoing High‐Risk Cardiac Surgery: A Randomized Phase 2b Clinical Trial
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Ann Eldred | 247 | 210 | 152 | 19 | 367 | |
| Giorgia Grosso | 198 | 136 | 44 | 19 | 312 | |
| Nicolò Girolimetto | 248 | 322 | 134 | 25 | 378 | |
| Miriam Teoli | 238 | 154 | 90 | 21 | 367 | |
| Rie Suematsu | 247 | 97 | 173 | 18 | 335 | |
| Jieruo Gu | 145 | 237 | 71 | 25 | 329 | |
| M. Lamba | 136 | 98 | 75 | 17 | 349 | |
| Sahar M. Abdel Galil | 145 | 203 | 40 | 17 | 382 | |
| María Laura Acosta Felquer | 251 | 300 | 162 | 15 | 367 | |
| Smriti Chaurasia | 151 | 192 | 35 | 20 | 402 | |
| Frederik Staels | 127 | 93 | 38 | 20 | 361 |
All Works
Loading papers...